MaaT Pharma (MAAT) Gets a Buy from Kepler Capital

Business Insider

3 days ago

Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on June 2 and set a price target of €15.50. The company's shares closed yesterday at €5.64.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
dombu covers the Healthcare sector, focusing on stocks such as MaaT Pharma, Basilea Pharmaceutica, and Nyxoah. According to TipRanks, dombu has an average return of -9.3% and a 39.62% success rate on recommended stocks.
Currently, the analyst consensus on MaaT Pharma is a Strong Buy with an average price target of €19.50.
The company has a one-year high of €9.96 and a one-year low of €4.70. Currently, MaaT Pharma has an average volume of 7,961.